In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
about
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroIn vitro activity of Ro 23-6240, a new fluorinated 4-quinoloneCiprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureusChemotherapeuticsComparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacinRandomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice.Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacinPharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosisCiprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disksA review of the antimicrobial activity of the fluoroquinolones.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Penetration of ciprofloxacin into human pleural fluid.Interaction of the fluoroquinolone antimicrobial agents ciprofloxacin and enoxacin with liposomesAltered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits.In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains.In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents.Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa.Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.A pilot study of piperacillin and ciprofloxacin as initial therapy for fever in severely neutropenic leukemia patients.Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination
P2860
Q24670241-FE3909E1-D04E-4F75-B72E-08A4E7BE5AECQ24685787-E79B54AF-3882-4C9B-8A90-C607E2966DADQ28361123-763D79F3-C13A-4C15-A529-F474F8FA2881Q30047670-69ACC5FC-4C1B-4C59-92B2-9786787F866AQ30451302-489BA848-24D3-4F10-9A68-2FAB17B588F5Q33739836-CA1EF7D8-1FFF-4427-BD61-00F48DF755BAQ35243644-FC761BE2-C5B5-4AC6-A937-719A28D07A37Q35288542-FE041B17-EB8F-4B49-B7D2-B7C2521BA0F0Q35303163-FDDACBC2-796E-415B-AE66-ABB73FA6CAFFQ35319641-B84A0CE1-60C8-434A-A255-B6575DD5585EQ35575446-85F4E58B-03F8-44CF-B776-F8C67706DA86Q37281766-EC17BADA-9DD3-4A00-A482-D07DC2FF9E31Q37834318-5CEE8B1A-111B-4DE3-A4E5-0E8F6F35BBD7Q39214819-03BC34F5-FBC4-43F5-8936-F228C498B894Q39816025-48FB6C13-0DF9-4DEA-B006-DA2BB04F22A0Q39819744-E60CC845-0621-4AAF-9BB2-AE506DA2C857Q39828385-49F63B98-BBB2-4942-9F71-909388A278A6Q39832394-CD713CD1-C755-437C-9928-CDFD158A8EC3Q39834358-C0DDDCE0-3411-4550-B3B5-C6AD5F8672C3Q39849307-BC807D54-3220-46F7-8CA6-C14BDADA4995Q39849561-7B4484C7-1AD8-405C-92CE-8C3CAC578512Q39849761-032F55E7-B998-45A6-A86B-376E68D1CA01Q39850437-13825B93-58CA-4907-8193-CF2C168CCB2FQ39869347-0E7C5DBA-077F-4ADD-A45D-A0F06558BC65Q40088425-5DFFF094-5951-4F76-837F-3BE51C10A4E7Q40283581-4D8356E9-D87E-40CB-8D89-9B3783EF829EQ40283892-F867B31A-4830-47EE-9220-B14AD2E3C375Q40285699-51538678-8BAB-40B3-8050-AB82718F4B7DQ40740367-534C414D-2444-4C63-A928-C156DBBC997CQ57240424-DBFFBF4D-600E-4A79-8649-969709BCA2B7
P2860
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
@en
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
@nl
type
label
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
@en
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
@nl
prefLabel
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
@en
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
@nl
P2093
P356
P1476
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
@en
P2093
P304
P356
10.1093/JAC/13.4.333
P407
P577
1984-04-01T00:00:00Z